BC Week In Review | Jun 16, 2014
Clinical News

MM-121: Additional Phase II data

Last year, Merrimack disclosed on a conference call to discuss its 2Q13 earnings that a pre-specified interim analysis of the trial by a DSMB showed that MM-121 plus paclitaxel would not meet the primary endpoint....
BC Week In Review | Jun 16, 2014
Clinical News

MM-121: Additional Phase II data

Additional data from a double-blind, placebo-controlled, international Phase II trial in 115 patients who have failed anti-estrogen therapy showed that IV MM-121 plus oral Aromasin exemestane led to a median PFS, the primary endpoint, of...
BC Week In Review | Jun 16, 2014
Clinical News

MM-121: Additional Phase II data

Additional data from 132 NSCLC patients with EGFR wild-type tumors in Group A of a single-arm, open-label, international Phase II trial showed that MM-121 plus Tarceva erlotinib led to a median PFS, the primary endpoint,...
BC Week In Review | Dec 9, 2013
Clinical News

MM-121: Phase II data

Data from 99 patients with estrogen receptor-positive and/or progesterone receptor-positive, HER2-negative breast cancer in the first cohort of an open-label, U.S. Phase II trial in 99 patients showed that weekly IV MM-121 plus paclitaxel followed...
BC Week In Review | Dec 9, 2013
Clinical News

MM-121: Phase II data

A double-blind, placebo-controlled, international Phase II trial in 118 patients who have failed anti-estrogen therapy showed that IV MM-121 plus oral Aromasin exemestane missed the primary endpoint of improving PFS with an HR of <=0.5...
BC Week In Review | Nov 4, 2013
Clinical News

MM-121: Phase II data

In August, Merrimack disclosed on a conference call to discuss its 2Q13 earnings that a pre-specified interim analysis of the trial by a DSMB showed that MM-121 plus paclitaxel would not meet the primary endpoint....
BC Week In Review | Aug 12, 2013
Clinical News

MM-121: Phase II data

Merrimack disclosed on a conference call to discuss its 2Q13 earnings that a pre-specified interim analysis by a DSMB of an open-label, international Phase II trial in 223 patients with platinum-resistant or refractory advanced ovarian...
BC Week In Review | Aug 12, 2013
Clinical News

MM-121: Phase II data

Merrimack disclosed on a conference call to discuss its 2Q13 earnings that it will stop enrollment in Group B of a single-arm, open-label, international Phase II trial after a pre-specified interim analysis by a DSMB...
Items per page:
1 - 8 of 8